Azitra(AZTR)

Focus: Azitra is a public-stage biotechnology company focused on microbiome-based skin treatments, headquartered in Branford, CT. The company operates as a pre-revenue biotech with minimal commercial traction and a research-intensive pipeline.

Gastroenterology

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Azitra

AI assessmentNot Hiring

No open roles listed right now. Follow Azitra to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$8K

FY2025

Pipeline & Clinical Trials

AZT-04

Skin Appearance

N/A

Clinical Trials (1)

NCT03820076Safety Study of AZT-04 for Cosmetic Use

N/A

Help build intelligence for Azitra

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage microbiome science in a high-growth therapeutic area with significant unmet need in dermatology and gastroenterology
Public company status provides equity upside potential and access to capital markets for funding clinical progression
Opportunity to shape company trajectory in a novel, differentiated technology platform before peak scale

Watch Out For

Company generated only $8K in FY 2025 revenue against $5M R&D spend, indicating no commercial revenue generation or market traction
Current cash position of $5M with negative net income of -$8.9M in FY 2025 creates short-to-medium term runway risk and potential dilution
Zero active job openings and minimal disclosure on headcount suggest frozen or highly selective hiring despite public status

Generated by Claude from Azitra's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ATR12-351

Netherton Syndrome

Phase 1

Clinical Trials (1)

NCT06137157Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Phase 1

ATR04-484

EGFR Inhibitor-associated Rash

Phase 1/2

Clinical Trials (1)

NCT06830863A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Phase 1/2

ATR-04

Papulopustular Rosacea

Phase 1/2

Clinical Trials (1)

NCT04731259Study to Evaluate the Safety of ATR-04

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Dermatology

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Dermatology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$8K99%

R&D Spend

$5M(62978%)30%

Net Income

-$9M